WOBURN, Mass., Jan. 26, 2011 /PRNewswire/ — Avantra®
Biosciences, a leading innovator in protein diagnostics, announced
today their first shipments of the new Q400 Biomarker Workstation
and the innovative Angio Qx™ BioChip Immunoassay. The system
provides quantitative protein biomarker results for ten analytes in
less than an hour, requiring less than five minutes for sample
preparation. Multiplex protein assays can be helpful in evaluating
the association between elevated protein levels, patient phenotype
and drug response.
The Angio Qx Immunoassay is a member of the Avantra QPDx™
biomarker detection product line for use with the Q400 Biomarker
Workstation. This platform consists of a completely
self-contained immunoassay BioChip and instrument, for use in the
automated measurement of key biomarkers.
Avantra is currently working with leading experts and
institutions on the development of additional biomarker panels
directed at specific diseases with an emphasis in the field of
oncology for research use only (RUO). Avantra intends to seek
regulatory approval for its assay technologies in the future.
The power and simplicity of Avantra’s QPDx platform offers users
a rapid, easy-to-use, high quality bench top quantitative multiplex
protein assay platform with extremely low CVs and very little setup
time.
“The initial shipment of Avantra’s QPDx biomarker product line
represents the first milestone in Avantra’s strategy to develop a
suite of oncology focused multiplex biomarker panels. We see
a tremendous opportunity for our QPDx product line and we are
excited about the work we are doing with our partners to
commercialize additional oncology specific biomarker panels,” says
Brian McKernan, CEO of Avantra.
About Avantra Biosciences Corporation
Avantra Biosciences is a privately held diagnostics company that
has pioneered next-generation technology for protein
biomarker
‘/>”/>
